0.95  0.018 (1.89%)		10-04 11:11
Open: 0.92 High: 0.981 Volume: 15,569		Pre. Close: 0.9324 Low: 0.92 Market Cap: 17(M)

Short term
Mid term
Targets	6-month :	1.33	1-year :	1.51
Resists	First :	1.14	Second :	1.29
Pivot price	1.02
Supports	First :	0.88	Second :	0.73
MAs	MA(5) :	0.97	MA(20) :	1.03
	MA(100) :	2.39	MA(250) :	2.83
MACD	MACD :	-0.2	Signal :	-0.2
%K %D	K(14,3) :	18.1	D(3) :	22.7
RSI	RSI(14): 31
52-week	High :	8.55	Low :	0.88

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ PHGE ] has closed above bottom band by 10.8%. Bollinger Bands are 75.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 21 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.97 - 0.98	0.98 - 0.98
Low:	0.86 - 0.87	0.87 - 0.88
Close:	0.92 - 0.94	0.94 - 0.95

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

Thu, 26 Sep 2024
BiomX Shares Phage Therapy Advances and Vision - TipRanks

Wed, 18 Sep 2024
BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference - StockTitan

Fri, 16 Aug 2024
UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split | PHGE Stock News - StockTitan

Thu, 15 Aug 2024
BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates - Yahoo Finance

Thu, 15 Aug 2024
BiomX Inc. Announces 1-for-10 Reverse Stock Split | PHGE Stock News - StockTitan

Thu, 15 Aug 2024
BiomX Inc. Announces 1-for-10 Reverse Stock Split - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	18 (M)
Shares Float	14 (M)
Held by Insiders	10.1 (%)
Held by Institutions	12.9 (%)
Shares Short	28 (K)
Shares Short P.Month	81 (K)

EPS	-3.91
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.73
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-32.7 %
Return on Equity (ttm)	-121.3 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.55
Qtrly Earnings Growth	0 %
Operating Cash Flow	-35 (M)
Levered Free Cash Flow	-17 (M)

PE Ratio	-0.25
PEG Ratio	0
Price to Book value	-1.31
Price to Sales	0
Price to Cash Flow	-0.49

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.